

Hearing loss epidemic One in ten (30 million) Americans has hearing loss - Causes include heredity, aging, noise exposure, disease - Number is expected to double by 2030 Hearing loss is the #1 birth defect in America - 1 in 1000 newborns is born profoundly deaf

- 2-3/1000 will have partial/progressive hearing loss

Hearing loss prevalence increases with age

- 1 in 3 over 65 years has significant hearing loss
- Among seniors, hearing loss is the 3rd most prevalent condition

2















- I. Generation of inner ear cells by gene therapy
- II. Generation of inner ear cells from stem cells
 in vitro followed by cell grafting
 from endogenous cells in vivo









Silencing of gene that controls cell division leads to new hair cells



Generate new hair cells from stem cells

• Approach 1:

- Generation of inner ear cell types from stem cells in a dish
- Injection of hair cells or neurons into the inner ear

• Approach 2:

• Generation of hair cells or neurons from stem cells in the animal

Generate new hair cells from stem cells Approach 1: Cells from exogenous sources

- Generate hair cells and neurons from exogenous stem cells
- Transplant cells into the inner ear





Adult Stem Cells

- Pluripotent (numerous cell types)
- Renewable
- No political issues for research use
- Avoid rejection problem because of autologous cells (from the same person)





























Challenges for drug delivery into the cochlea

Cochlea is protected from most drugs applied to the bloodstream.

Cochlear fluid space is very small and sensitive to changes in fluid volume.

Useful drugs may be unstable over long periods of time in solution.

Frequent drug refills may introduce bacterial contamination.

Getting drugs to their targets: systemic vs. local delivery

For therapies based on these discoveries to become clinically useful, need to develop safe and reliable methods for delivery of complex compounds *directly* into the inner ear.

> Better hearing through chemistry: inner ear drug delivery



Blood-Cochlea Barrier:

Prevents ready access to cochlea (good and bad)

Future therapies based on complex compounds will benefit from *direct* intracochlear delivery

